Printed from Voxsanity (voxsanity.com.au) — NCT06911931 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Schizophrenia
Schizophrenia Trial, Recruiting
NCT06911931
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 65 years old
- People with vision of 20/32 or better, including with glasses or contact lenses if needed
- People who can speak English well enough to complete the study tasks and give informed consent
- People diagnosed with schizophrenia, schizoaffective disorder, or schizophreniform disorder, confirmed using a structured diagnostic interview (SCID-5)
- People diagnosed with bipolar disorder (type I, type II, or unspecified), confirmed using a structured diagnostic interview (SCID-5)
Who may not be able to join:
- People who are unable to read, understand instructions, or give informed consent
- People with significant intellectual impairment, based on a standardised reading and ability test (at the discretion of the research team)
- People who are actively under the influence of alcohol or drugs at the time of the study
- People who have had a substance use disorder in the past 3 months
- People considered to be at high risk of suicide, including those with active suicidal thoughts or a suicide attempt in the 30 days before screening
- People who have shown violent behaviour involving severe or potentially lethal means, or any violence in the past 6 months, or who are extremely agitated
- People who are currently in a manic episode
- People who have had a head injury with loss of consciousness lasting more than 10 minutes (at the discretion of the research team)
- People who have had electroconvulsive therapy (ECT) in the past 8 weeks
- People diagnosed with a neurological condition such as a brain tumour, stroke, brain injury, seizure disorder, or a pervasive developmental disorder
- People with a lazy eye, squint, or any other known eye condition
- For healthy control participants: people with any history of a psychotic disorder or psychiatric hospitalisation
- For healthy control participants: people who have taken antidepressants, mood stabilisers, or antipsychotic medications daily in the past 6 months, or benzodiazepines in the past 2 days
- For healthy control participants: people with a close blood relative (parent, sibling, or child) diagnosed with a schizophrenia spectrum disorder or bipolar disorder
- For case-matched control participants (non-ill): people with any history of a psychotic disorder, recurrent or current depression, persistent psychotic symptoms, or psychiatric hospitalisation
- For case-matched control participants (non-ill): people who have taken antidepressants, mood stabilisers, or antipsychotic medications daily in the past 6 months, or benzodiazepines in the past 2 days
- For case-matched control participants (non-ill): people with a close blood relative diagnosed with a schizophrenia spectrum disorder or bipolar disorder
- For bipolar disorder participants: people with persistent psychotic symptoms that meet a clinical threshold (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
Contact this trial
Phone: 585-275-3077
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
3 November 2025
Est. completion
31 January 2027
Where this trial is recruiting
🇺🇸 United States
Primary endpoints
mean amplitude of EEG visual response
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.